董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Terrie Curran | 女 | Director | 52 | 36.03万美元 | 5.81 | 2021-07-23 |
| Mark J. Guinan | 男 | Director | 59 | 35.28万美元 | 1.50 | 2021-07-23 |
| Adele Gulfo | 女 | Director | 58 | 33.78万美元 | 未持股 | 2021-07-23 |
| Hiroshi Nomura | 男 | Director | 63 | 未披露 | 未持股 | 2021-07-23 |
| David Marek | 男 | Principal Executive Officer and Director,Chief Executive Officer | 56 | 1027.62万美元 | 未持股 | 2021-07-23 |
| Myrtle Potter | 女 | Chairman of the Board, Director | 62 | 37.28万美元 | 未持股 | 2021-07-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Matthew Lang | 男 | General Counsel and Corporate Secretary,Chief Legal and Administrative Officer and Corporate Secretary,General Manager of Myovant Sciences GmbH | 45 | 283.31万美元 | 18.22 | 2021-07-23 |
| Juan Camilo Arjona Ferreira | 男 | Chief Medical Officer | 51 | 197.86万美元 | 14.51 | 2021-07-23 |
| David Marek | 男 | Principal Executive Officer and Director,Chief Executive Officer | 56 | 1027.62万美元 | 未持股 | 2021-07-23 |
| Lauren Merendino | 女 | Chief Commercial Officer | 46 | 未披露 | 未持股 | 2021-07-23 |
| Frank Karbe | 男 | Principal Financial and Accounting Officer,President and Chief Financial Officer o | 53 | 298.84万美元 | 29.90 | 2021-07-23 |
董事简历
中英对照 | 中文 | 英文- Terrie Curran
-
Terrie Curran自2019年8月以来一直担任我们的董事会成员。作为计划过渡的一部分，Curran女士于2019年12月2日接替Socks先生担任首席执行官。Curran女士此前曾于2017年4月至2019年11月担任新基医药公司全球炎症和免疫专营权总裁，并担任其执行委员会成员。Curran女士于2013年加入Celgene，担任I&I特许经营权的美国商业主管，并在成为全球市场主管之前建立了能力并招募了成功推出Otezla的团队。加入Celgene公司之前，她曾担任默克公司（Merck&Co.）的高级副总裁兼全球女性健康总经理。加入Merck之前，Curran女士在欧洲和亚太地区的先灵葆雅（Schering-Plough）和Pharmacia担任过多个国家总经理职位。她目前任职于生物技术公司Myovant SciencesLtd.的董事会，此前曾任职于全球制药公司H.Lundbeck A/S的董事会。Curran女士拥有悉尼科技大学（University of Technology，Sydney）的市场营销研究生文凭和应用科学B.A.S.学士学位。
Terrie Curran has served as a member of the Board since November 2016. Ms. Curran has served as the Chief Executive Officer at Phathom Pharmaceuticals, Inc., a pharmaceutical company, since December 2019 and has served as the President of Phathom Pharmaceuticals since November 2020. From April 2017 to November 2019 Ms. Curran served as President, Global Inflammation and Immunology Franchise of Celgene Corporation, a biotechnology company, and as a member of its Executive Committee. Previously, she was Head of Worldwide Markets for Celgene’s Global Inflammation and Immunology Franchise. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the Global Inflammation and Immunology Franchise and built the capabilities and recruited the teams that executed the successful U.S. launch of OTEZLA®. Before Celgene, she served as Senior Vice President and General Manager - Global Women’s Health business at Merck and Co., Inc. At Merck, she was responsible for all commercial activities within the global business and led a number of successful global product launches. Prior to Merck, Ms. Curran was a General Manager at Schering-Plough where she successfully launched Remicade in Switzerland and Australia. Ms. Curran currently serves on the boards of directors of Phathom Pharmaceuticals and Arcutis Biotherapeutics, Inc., both pharmaceutical companies. From March 2014 to March 2017 Ms. Curran served as a director of H. Lundbeck A/S, a global pharmaceutical company specialized in psychiatric and neurological disorders. Ms. Curran received her B.S. and Graduate Diploma of Marketing degrees from the University of Technology in Sydney, Australia. - Terrie Curran自2019年8月以来一直担任我们的董事会成员。作为计划过渡的一部分，Curran女士于2019年12月2日接替Socks先生担任首席执行官。Curran女士此前曾于2017年4月至2019年11月担任新基医药公司全球炎症和免疫专营权总裁，并担任其执行委员会成员。Curran女士于2013年加入Celgene，担任I&I特许经营权的美国商业主管，并在成为全球市场主管之前建立了能力并招募了成功推出Otezla的团队。加入Celgene公司之前，她曾担任默克公司（Merck&Co.）的高级副总裁兼全球女性健康总经理。加入Merck之前，Curran女士在欧洲和亚太地区的先灵葆雅（Schering-Plough）和Pharmacia担任过多个国家总经理职位。她目前任职于生物技术公司Myovant SciencesLtd.的董事会，此前曾任职于全球制药公司H.Lundbeck A/S的董事会。Curran女士拥有悉尼科技大学（University of Technology，Sydney）的市场营销研究生文凭和应用科学B.A.S.学士学位。
- Terrie Curran has served as a member of the Board since November 2016. Ms. Curran has served as the Chief Executive Officer at Phathom Pharmaceuticals, Inc., a pharmaceutical company, since December 2019 and has served as the President of Phathom Pharmaceuticals since November 2020. From April 2017 to November 2019 Ms. Curran served as President, Global Inflammation and Immunology Franchise of Celgene Corporation, a biotechnology company, and as a member of its Executive Committee. Previously, she was Head of Worldwide Markets for Celgene’s Global Inflammation and Immunology Franchise. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the Global Inflammation and Immunology Franchise and built the capabilities and recruited the teams that executed the successful U.S. launch of OTEZLA®. Before Celgene, she served as Senior Vice President and General Manager - Global Women’s Health business at Merck and Co., Inc. At Merck, she was responsible for all commercial activities within the global business and led a number of successful global product launches. Prior to Merck, Ms. Curran was a General Manager at Schering-Plough where she successfully launched Remicade in Switzerland and Australia. Ms. Curran currently serves on the boards of directors of Phathom Pharmaceuticals and Arcutis Biotherapeutics, Inc., both pharmaceutical companies. From March 2014 to March 2017 Ms. Curran served as a director of H. Lundbeck A/S, a global pharmaceutical company specialized in psychiatric and neurological disorders. Ms. Curran received her B.S. and Graduate Diploma of Marketing degrees from the University of Technology in Sydney, Australia.
- Mark J. Guinan
-
Mark J. Guinan自2018年7月起担任董事会成员。2013年7月以来，他担任Quest Diagnostics Incorporated(诊断信息服务提供商)的执行副总裁兼首席财务官。从2010年到2013年，他担任Hill-Rom Holdings Inc.(医疗技术和医疗保健行业相关服务的制造商和供应商)的首席财务官。此前，他在Johnson & Johnson的长期职业生涯中担任多个财务和运营职务，包括2009年至2010年担任副总裁兼首席采购官，2005年至2009年担任集团金融制药副总裁。在1997年加入强生公司之前，他曾在宝洁公司担任多个财务职务。他获得了圣母大学(University of Notre Dame)的经济学学士学位和圣路易斯华盛顿大学(Washington University)奥林商学院(Olin Business School)的工商管理硕士学位。
Mark J. Guinan has served as a member of the Board since July 2018. Since July 2013 Mr. Guinan has served as the Executive Vice President and Chief Financial Officer at Quest Diagnostics Incorporated, a provider of diagnostic information services. From 2010 to 2013 he served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the health care industry. Previously, he served in a number of finance and operations roles in a long career at Johnson & Johnson including from 2009 to 2010 as Vice President, Chief Procurement Officer, and 2005 to 2009 as Vice President, Group Finance Pharmaceuticals. Before joining Johnson & Johnson in 1997 he held a number of finance roles at Procter & Gamble. Mr. Guinan received his B.A. in Economics from the University of Notre Dame and his M.B.A. from Olin Business School at the Washington University in St. Louis. - Mark J. Guinan自2018年7月起担任董事会成员。2013年7月以来，他担任Quest Diagnostics Incorporated(诊断信息服务提供商)的执行副总裁兼首席财务官。从2010年到2013年，他担任Hill-Rom Holdings Inc.(医疗技术和医疗保健行业相关服务的制造商和供应商)的首席财务官。此前，他在Johnson & Johnson的长期职业生涯中担任多个财务和运营职务，包括2009年至2010年担任副总裁兼首席采购官，2005年至2009年担任集团金融制药副总裁。在1997年加入强生公司之前，他曾在宝洁公司担任多个财务职务。他获得了圣母大学(University of Notre Dame)的经济学学士学位和圣路易斯华盛顿大学(Washington University)奥林商学院(Olin Business School)的工商管理硕士学位。
- Mark J. Guinan has served as a member of the Board since July 2018. Since July 2013 Mr. Guinan has served as the Executive Vice President and Chief Financial Officer at Quest Diagnostics Incorporated, a provider of diagnostic information services. From 2010 to 2013 he served as Chief Financial Officer for Hill-Rom Holdings Inc., a manufacturer and provider of medical technologies and related services for the health care industry. Previously, he served in a number of finance and operations roles in a long career at Johnson & Johnson including from 2009 to 2010 as Vice President, Chief Procurement Officer, and 2005 to 2009 as Vice President, Group Finance Pharmaceuticals. Before joining Johnson & Johnson in 1997 he held a number of finance roles at Procter & Gamble. Mr. Guinan received his B.A. in Economics from the University of Notre Dame and his M.B.A. from Olin Business School at the Washington University in St. Louis.
- Adele Gulfo
-
Adele Gulfo自2020年5月起担任我们的临时首席商务官，并在生物制药公司Sumitovant Biopharma，Inc.（Sumitovant的子公司）担任首席业务和商业开发官，自2019年12月起，她负责监督跨多种渠道的全球业务开发和商业化活动。住友制药（Sumitovant）是住友大日本制药（Sumitomo Dainippon Pharma）的全资子公司，于2019年12月经营着从我们的前控股股东Roivant收购的五家生物制药公司，是我们的大股东。从2018年5月至2019年12月，Gulfo女士担任制药公司Roivant的商业开发主管，负责指导业务开发活动并监督商业化战略。在2018年5月加入Roivant之前，古尔弗曾担任全球制药公司MylanN.V.（McKinsey）的执行Vice President和全球商业开发主管，从2014年1月至2018年1月，她负责开发和实施生物仿制药，品牌仿制药和特种药品的营销和商业化战略。在加入Mylan之前，Gulfo女士在辉瑞公司工作了五年，担任过多个执行职位，包括美国初级保健部门的总裁兼总经理。加入Pfizer公司之前，她曾担任AstraZeneca Pharmaceuticals公司、Warner-Lambert公司（后来与Pfizer公司合并）的Parke-Davis部门的多种执行职务，也曾担任高级董事，为该公司的心血管营销，她推出了Lipitor，最畅销的制药产品。Gulfo女士目前担任EnproIndustries，Inc.（一家生产专有工程工业产品的公司）和Medexus Pharmaceuticals，Inc.（一家制药公司）的董事会成员。2015年6月至2019年6月，Gulfo女士担任制造公司BemisCompany，Inc.的董事会成员。Gulfo女士还在Partners梦百合的创新成长委员会任职，并且是Springboard生命科学公司的顾问。Gulfo女士在Seton Hall University获得生物学学士学位，在Fairleigh Dickinson University-Florham Campus获得市场营销工商管理硕士学位（最高荣誉）。她曾学习研究生分子生物学，并在新泽西大学（the University of Medicine and Dentrestry of New Jersey）开始她的职业生涯。
Adele Gulfo,Since December 2019 Ms. Gulfo has served as Chief Commercial and Business Development Officer at Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant Biopharma Ltd., in which capacity she is responsible for overseeing global business development and commercialization activities across a diverse pipeline. Sumitovant Biopharma Ltd. is our majority shareholder and a wholly-owned subsidiary of Sumitomo Dainippon Pharma. From May 2020 to March 2021 Ms. Gulfo served as the Interim Chief Commercial Officer of Myovant Sciences, Inc. From May 2018 to December 2019 Ms. Gulfo served as Chief of Commercial Development at Roivant, a pharmaceutical company, in which capacity she was responsible for directing business development activities and overseeing commercialization strategies. Prior to joining Roivant in May 2018 Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V., a global pharmaceuticals company, from January 2014 to January 2018 in which capacity she was responsible for developing and implementing strategies of marketing and commercialization of biosimilars, branded generic, and specialty pharmaceutical products. Before joining Mylan, Ms. Gulfo spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U.S. Primary Care. She also ran Commercial Operations and the Managed Markets organization across Pfizer’s biopharmaceutical business in the U.S. Prior to joining Pfizer, she held several executive positions at AstraZeneca Pharmaceuticals and at the Parke-Davis division of Warner-Lambert which later merged with Pfizer, and, as the Senior Director, Cardiovascular Marketing for that company, she launched Lipitor, the best-selling pharmaceutical product. Ms. Gulfo currently serves on the board of directors of EnPro Industries, Inc., a company producing proprietary engineered industrial products, and Medexus Pharmaceuticals, Inc., a pharmaceutical company. From June 2015 to June 2019 Ms. Gulfo served on the board of directors of Bemis Company, Inc., a manufacturing company. Ms. Gulfo also serves on the Innovation Growth Board for Partners Healthcare and is an advisor for Springboard Life Sciences. Ms. Gulfo received her B.S. in Biology from Seton Hall University, and her M.B.A. (with highest honors) in Marketing from Fairleigh Dickinson University-Florham Campus. She studied post-graduate Molecular Biology and began her career at the University of Medicine and Dentistry of New Jersey. - Adele Gulfo自2020年5月起担任我们的临时首席商务官，并在生物制药公司Sumitovant Biopharma，Inc.（Sumitovant的子公司）担任首席业务和商业开发官，自2019年12月起，她负责监督跨多种渠道的全球业务开发和商业化活动。住友制药（Sumitovant）是住友大日本制药（Sumitomo Dainippon Pharma）的全资子公司，于2019年12月经营着从我们的前控股股东Roivant收购的五家生物制药公司，是我们的大股东。从2018年5月至2019年12月，Gulfo女士担任制药公司Roivant的商业开发主管，负责指导业务开发活动并监督商业化战略。在2018年5月加入Roivant之前，古尔弗曾担任全球制药公司MylanN.V.（McKinsey）的执行Vice President和全球商业开发主管，从2014年1月至2018年1月，她负责开发和实施生物仿制药，品牌仿制药和特种药品的营销和商业化战略。在加入Mylan之前，Gulfo女士在辉瑞公司工作了五年，担任过多个执行职位，包括美国初级保健部门的总裁兼总经理。加入Pfizer公司之前，她曾担任AstraZeneca Pharmaceuticals公司、Warner-Lambert公司（后来与Pfizer公司合并）的Parke-Davis部门的多种执行职务，也曾担任高级董事，为该公司的心血管营销，她推出了Lipitor，最畅销的制药产品。Gulfo女士目前担任EnproIndustries，Inc.（一家生产专有工程工业产品的公司）和Medexus Pharmaceuticals，Inc.（一家制药公司）的董事会成员。2015年6月至2019年6月，Gulfo女士担任制造公司BemisCompany，Inc.的董事会成员。Gulfo女士还在Partners梦百合的创新成长委员会任职，并且是Springboard生命科学公司的顾问。Gulfo女士在Seton Hall University获得生物学学士学位，在Fairleigh Dickinson University-Florham Campus获得市场营销工商管理硕士学位（最高荣誉）。她曾学习研究生分子生物学，并在新泽西大学（the University of Medicine and Dentrestry of New Jersey）开始她的职业生涯。
- Adele Gulfo,Since December 2019 Ms. Gulfo has served as Chief Commercial and Business Development Officer at Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant Biopharma Ltd., in which capacity she is responsible for overseeing global business development and commercialization activities across a diverse pipeline. Sumitovant Biopharma Ltd. is our majority shareholder and a wholly-owned subsidiary of Sumitomo Dainippon Pharma. From May 2020 to March 2021 Ms. Gulfo served as the Interim Chief Commercial Officer of Myovant Sciences, Inc. From May 2018 to December 2019 Ms. Gulfo served as Chief of Commercial Development at Roivant, a pharmaceutical company, in which capacity she was responsible for directing business development activities and overseeing commercialization strategies. Prior to joining Roivant in May 2018 Ms. Gulfo served as Executive Vice President and Head of Global Commercial Development for Mylan N.V., a global pharmaceuticals company, from January 2014 to January 2018 in which capacity she was responsible for developing and implementing strategies of marketing and commercialization of biosimilars, branded generic, and specialty pharmaceutical products. Before joining Mylan, Ms. Gulfo spent five years at Pfizer Inc. in a number of executive positions, including President and General Manager, U.S. Primary Care. She also ran Commercial Operations and the Managed Markets organization across Pfizer’s biopharmaceutical business in the U.S. Prior to joining Pfizer, she held several executive positions at AstraZeneca Pharmaceuticals and at the Parke-Davis division of Warner-Lambert which later merged with Pfizer, and, as the Senior Director, Cardiovascular Marketing for that company, she launched Lipitor, the best-selling pharmaceutical product. Ms. Gulfo currently serves on the board of directors of EnPro Industries, Inc., a company producing proprietary engineered industrial products, and Medexus Pharmaceuticals, Inc., a pharmaceutical company. From June 2015 to June 2019 Ms. Gulfo served on the board of directors of Bemis Company, Inc., a manufacturing company. Ms. Gulfo also serves on the Innovation Growth Board for Partners Healthcare and is an advisor for Springboard Life Sciences. Ms. Gulfo received her B.S. in Biology from Seton Hall University, and her M.B.A. (with highest honors) in Marketing from Fairleigh Dickinson University-Florham Campus. She studied post-graduate Molecular Biology and began her career at the University of Medicine and Dentistry of New Jersey.
- Hiroshi Nomura
-
Hiroshi Nomura自2018年4月起担任Sumitomo Dainippon Pharma的总裁，首席执行官和代表董事，该公司是总部位于日本的制药公司，也是Sumitovant的唯一股东。Sumitovant是住友大日本制药（Sumitomo Dainippon Pharma）的全资子公司，经营着2019年12月从Roivant收购的五家生物制药公司，是我们的大股东。在担任现任职务之前，Nomura先生还在Sumitomo Dainippon Pharma担任过多个执行领导职务，包括担任董事会成员，高级执行官，2017年4月至2018年4月担任首席财务官兼代表董事，并于2014年4月至2017年4月担任董事会成员，高级执行官兼首席财务官。在此之前，Nomura先生还于2005年10月至2014年4月在Sumitomo Dainippon Pharma担任其他各种职责递增的职位。Nomura先生目前在Sumitomo Dainippon Pharma，Sumitovant，Boston Biomedical，Inc.和Tolaro Pharmaceuticals，Inc.的董事会任职，这些公司都是一家制药公司。2011年2月至2014年4月，他还担任制药公司Sunovion Pharmaceuticals Inc.的Vice Chairman of the Board。Nomura先生在University of Tokyo获得经济学学位。
Hiroshi Nomura,Since April 2018 Mr. Nomura has served as President, Chief Executive Officer, and Representative Director of Sumitomo Dainippon Pharma, a pharmaceutical company based in Japan and the sole shareholder of Sumitovant Biopharma Ltd. Before serving at his current position, Mr. Nomura also served in a number of executive leadership roles at Sumitomo Dainippon Pharma, including as a member of the Board of Directors, Senior Executive Officer, Chief Finance Officer and Representative Director between April 2017 and April 2018 and as a member of the Board of Directors, Senior Executive Officer and Chief Finance Officer from April 2014 to April 2017. Before that, Mr. Nomura also held various other positions with increasing responsibilities at Sumitomo Dainippon Pharma from October 2005 to April 2014. Mr. Nomura currently serves on the boards of directors of Sumitomo Dainippon Pharma, Sumitovant Biopharma and Sumitomo Dainippon Pharma Oncology, Inc., a pharmaceutical company which was formed by a merger between Boston Biomedical, Inc. and Tolero Pharmaceuticals, Inc. in 2020. He also served as Vice Chairman of the board of directors of Sunovion Pharmaceuticals Inc., a pharmaceutical company, from February 2011 to April 2014. Mr. Nomura received an economics degree from University of Tokyo. - Hiroshi Nomura自2018年4月起担任Sumitomo Dainippon Pharma的总裁，首席执行官和代表董事，该公司是总部位于日本的制药公司，也是Sumitovant的唯一股东。Sumitovant是住友大日本制药（Sumitomo Dainippon Pharma）的全资子公司，经营着2019年12月从Roivant收购的五家生物制药公司，是我们的大股东。在担任现任职务之前，Nomura先生还在Sumitomo Dainippon Pharma担任过多个执行领导职务，包括担任董事会成员，高级执行官，2017年4月至2018年4月担任首席财务官兼代表董事，并于2014年4月至2017年4月担任董事会成员，高级执行官兼首席财务官。在此之前，Nomura先生还于2005年10月至2014年4月在Sumitomo Dainippon Pharma担任其他各种职责递增的职位。Nomura先生目前在Sumitomo Dainippon Pharma，Sumitovant，Boston Biomedical，Inc.和Tolaro Pharmaceuticals，Inc.的董事会任职，这些公司都是一家制药公司。2011年2月至2014年4月，他还担任制药公司Sunovion Pharmaceuticals Inc.的Vice Chairman of the Board。Nomura先生在University of Tokyo获得经济学学位。
- Hiroshi Nomura,Since April 2018 Mr. Nomura has served as President, Chief Executive Officer, and Representative Director of Sumitomo Dainippon Pharma, a pharmaceutical company based in Japan and the sole shareholder of Sumitovant Biopharma Ltd. Before serving at his current position, Mr. Nomura also served in a number of executive leadership roles at Sumitomo Dainippon Pharma, including as a member of the Board of Directors, Senior Executive Officer, Chief Finance Officer and Representative Director between April 2017 and April 2018 and as a member of the Board of Directors, Senior Executive Officer and Chief Finance Officer from April 2014 to April 2017. Before that, Mr. Nomura also held various other positions with increasing responsibilities at Sumitomo Dainippon Pharma from October 2005 to April 2014. Mr. Nomura currently serves on the boards of directors of Sumitomo Dainippon Pharma, Sumitovant Biopharma and Sumitomo Dainippon Pharma Oncology, Inc., a pharmaceutical company which was formed by a merger between Boston Biomedical, Inc. and Tolero Pharmaceuticals, Inc. in 2020. He also served as Vice Chairman of the board of directors of Sunovion Pharmaceuticals Inc., a pharmaceutical company, from February 2011 to April 2014. Mr. Nomura received an economics degree from University of Tokyo.
- David Marek
-
David Marek自2021年1月起担任董事会成员和我们的首席执行官，以及Myovant Sciences，Inc.（我们的全资子公司）的首席执行官。Marek先生从2019年9月到2020年12月担任AxsomeTherapeutics，Inc.（制药公司）的首席商务官，在那里他领导建立商业能力，为预期的产品发布做准备。在加入Axsome之前，Marek先生从2017年6月到2019年8月担任Amgen，Inc.（制药公司）的副总裁兼神经科学业务部总经理。在安进，马雷克领导了美国的商业化战略，并推出了Aimovig预防偏头痛。在领导神经科学业务单元之前，他曾担任Amgen’；S美国炎症和肾病学业务的营销副总裁（从2015年6月到2017年6月），负责管理收入预测，产品战略，以及Amgen美国炎症和肾病学业务的业务规划。在Amgen之前，Marek先生是Turnstone Strategies LLC的负责人和所有者，该公司是一家咨询公司，提供健康与健康、数字健康、企业战略、营销和各种其他事务的咨询服务。在此之前，Marek先生担任Webmd HealthCorp.（健康信息服务供应商）的执行副总裁、消费者服务和商业战略官。在担任WebMD的这一职位之前，Marek先生是Saatchi&Saatchi医疗保健Advertising的总经理，这是一家跨国通信和广告代理网络。他的职业生涯始于礼来公司（一家制药公司），随后是AstraZeneca（一家跨国制药和生物技术公司），在那里他担任各种市场营销与销售职务，责任越来越大。他在华盛顿州立大学（Washington State University）获得工商管理学士学位。
David Marek has served as a member of the Board and our Principal Executive Officer, and as Chief Executive Officer of Myovant Sciences, Inc., our wholly-owned subsidiary, since January 2021. Mr. Marek served as Chief Commercial Officer of Axsome Therapeutics, Inc., a pharmaceutical company, where he led the buildout of commercial capabilities in preparation for anticipated product launches, from September 2019 to December 2020. Prior to joining Axsome, from June 2017 to August 2019 Mr. Marek held the position of Vice President, and General Manager of the Neuroscience business unit at Amgen, Inc., a pharmaceutical company. At Amgen, Mr. Marek led the U.S. commercialization strategy and launch of Aimovig for migraine prevention. Prior to heading the Neuroscience business unit, he was Vice President of Marketing of Amgen’s U.S. Inflammation and Nephrology business from June 2015 to June 2017 in which role he was responsible for managing revenue forecasts, product strategies, and business planning for the U.S. Inflammation and Nephrology business of Amgen. Before Amgen, Mr. Marek was the principal and owner of Turnstone Strategies LLC, which was a consulting firm providing consulting services on health and wellness, digital health, corporate strategy, marketing, and various other matters. Prior to that position, Mr. Marek served as Executive Vice President, Consumer Services, and Commercial Strategy Officer of WebMD Health Corp., a provider of health information services. Prior to this position at WebMD, Mr. Marek was the Managing Director of Saatchi & Saatchi Healthcare Advertising, a multinational communications and advertising agency network. Mr. Marek began his career at Eli Lilly and Company, a pharmaceutical company, followed by AstraZeneca, a multinational pharmaceutical and biotechnology company, where he served in a variety of marketing and sales roles of increasing responsibility. He earned his Bachelor of Arts degree in Business Administration from Washington State University. - David Marek自2021年1月起担任董事会成员和我们的首席执行官，以及Myovant Sciences，Inc.（我们的全资子公司）的首席执行官。Marek先生从2019年9月到2020年12月担任AxsomeTherapeutics，Inc.（制药公司）的首席商务官，在那里他领导建立商业能力，为预期的产品发布做准备。在加入Axsome之前，Marek先生从2017年6月到2019年8月担任Amgen，Inc.（制药公司）的副总裁兼神经科学业务部总经理。在安进，马雷克领导了美国的商业化战略，并推出了Aimovig预防偏头痛。在领导神经科学业务单元之前，他曾担任Amgen’；S美国炎症和肾病学业务的营销副总裁（从2015年6月到2017年6月），负责管理收入预测，产品战略，以及Amgen美国炎症和肾病学业务的业务规划。在Amgen之前，Marek先生是Turnstone Strategies LLC的负责人和所有者，该公司是一家咨询公司，提供健康与健康、数字健康、企业战略、营销和各种其他事务的咨询服务。在此之前，Marek先生担任Webmd HealthCorp.（健康信息服务供应商）的执行副总裁、消费者服务和商业战略官。在担任WebMD的这一职位之前，Marek先生是Saatchi&Saatchi医疗保健Advertising的总经理，这是一家跨国通信和广告代理网络。他的职业生涯始于礼来公司（一家制药公司），随后是AstraZeneca（一家跨国制药和生物技术公司），在那里他担任各种市场营销与销售职务，责任越来越大。他在华盛顿州立大学（Washington State University）获得工商管理学士学位。
- David Marek has served as a member of the Board and our Principal Executive Officer, and as Chief Executive Officer of Myovant Sciences, Inc., our wholly-owned subsidiary, since January 2021. Mr. Marek served as Chief Commercial Officer of Axsome Therapeutics, Inc., a pharmaceutical company, where he led the buildout of commercial capabilities in preparation for anticipated product launches, from September 2019 to December 2020. Prior to joining Axsome, from June 2017 to August 2019 Mr. Marek held the position of Vice President, and General Manager of the Neuroscience business unit at Amgen, Inc., a pharmaceutical company. At Amgen, Mr. Marek led the U.S. commercialization strategy and launch of Aimovig for migraine prevention. Prior to heading the Neuroscience business unit, he was Vice President of Marketing of Amgen’s U.S. Inflammation and Nephrology business from June 2015 to June 2017 in which role he was responsible for managing revenue forecasts, product strategies, and business planning for the U.S. Inflammation and Nephrology business of Amgen. Before Amgen, Mr. Marek was the principal and owner of Turnstone Strategies LLC, which was a consulting firm providing consulting services on health and wellness, digital health, corporate strategy, marketing, and various other matters. Prior to that position, Mr. Marek served as Executive Vice President, Consumer Services, and Commercial Strategy Officer of WebMD Health Corp., a provider of health information services. Prior to this position at WebMD, Mr. Marek was the Managing Director of Saatchi & Saatchi Healthcare Advertising, a multinational communications and advertising agency network. Mr. Marek began his career at Eli Lilly and Company, a pharmaceutical company, followed by AstraZeneca, a multinational pharmaceutical and biotechnology company, where he served in a variety of marketing and sales roles of increasing responsibility. He earned his Bachelor of Arts degree in Business Administration from Washington State University.
- Myrtle Potter
-
Myrtle Potter，2010年9月起，她担任我公司董事会成员。2007年7月起，她担任私人咨询公司Myrtle Potter & Company, LLC的首席执行官和创始人。2009年8月起，她担任消费者医疗保健公司Myrtle Potter Media, Inc.的创始人和首席执行官。2005年6月至2012年7月，她担任Chapman Properties, Inc.的首席执行官， 该公司属于她拥有的一家不动产销售、融资和开发公司。2000年5月至2005年9月，她就职于生物技术公司Genentech, Inc.， 最近担任商业运营总裁。她目前是一流药店连锁Rite Aid Corporation和许多私人公司的董事会成员，过去5年间，她曾担任亚马逊（Amazon.com, Inc.）， Medco Health Solutions Inc.和Express Scripts Holding Co的董事会成员。她在芝加哥大学（University of Chicago）获得学士学位。
Myrtle Potter has served as a member of the Board since September 2018 and has served as the Chairman of the Board since November 2018. Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant Biopharma Ltd. since December 2019. Sumitovant Biopharma Ltd. is our majority shareholder and a wholly-owned subsidiary of Sumitomo Dainippon Pharma. From July 2018 to December 2019 Ms. Potter served as Vant Operating Chair of Roivant Sciences, Inc, a pharmaceutical company. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences advisory firm, in September 2005 and served as its Chief Executive Officer until June 2018. From August 2009 until December 2014 Ms. Potter served as Founder and Chief Executive Officer of Myrtle Potter Media, Inc., a consumer healthcare company. From 2000 to 2004 Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005 she served as its President, Commercial Operations and Executive Vice President. Prior to that, Ms. Potter held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb and as a Vice President at Merck & Co. Ms. Potter currently serves on the board of directors of Liberty Mutual Holding Company Inc., a diversified global insurance company and several privately held companies, including Urovant Sciences Ltd., a biopharmaceutical company which ceased to be a public company in March 2021 as a result of Sumitovant acquiring all of the outstanding shares of Urovant not previously held by Sumitovant. Ms. Potter previously served on the boards of directors of Axsome Therapeutics, Inc., a biopharmaceutical company, from June 2017 to June 2020 Immunovant, Inc., a biopharmaceutical company, from December 2019 to February 2020 Axovant Gene Therapies Ltd., a biopharmaceutical company, from September 2018 to February 2020 Arbutus Biopharma Corporation, a biopharmaceutical company, from October 2018 to February 2020 INSMED Incorporated, a biopharmaceutical company, from December 2014 to November 2018 Rite Aid Corporation, a leading drugstore chain, from December 2013 to September 2018 Everyday Health, Inc., a leading provider of digital health and wellness solutions, from October 2010 until its acquisition in December 2016 and Amazon.com, Inc., a leading e-commerce company, from 2004 to 2009. She also served on the boards of directors of Medco Health Solutions Inc. and Express Scripts Holding Co., subsequent to its acquisition of Medco Health Solutions, as well as other privately held companies. Ms. Potter earned a B.A. from the University of Chicago. - Myrtle Potter，2010年9月起，她担任我公司董事会成员。2007年7月起，她担任私人咨询公司Myrtle Potter & Company, LLC的首席执行官和创始人。2009年8月起，她担任消费者医疗保健公司Myrtle Potter Media, Inc.的创始人和首席执行官。2005年6月至2012年7月，她担任Chapman Properties, Inc.的首席执行官， 该公司属于她拥有的一家不动产销售、融资和开发公司。2000年5月至2005年9月，她就职于生物技术公司Genentech, Inc.， 最近担任商业运营总裁。她目前是一流药店连锁Rite Aid Corporation和许多私人公司的董事会成员，过去5年间，她曾担任亚马逊（Amazon.com, Inc.）， Medco Health Solutions Inc.和Express Scripts Holding Co的董事会成员。她在芝加哥大学（University of Chicago）获得学士学位。
- Myrtle Potter has served as a member of the Board since September 2018 and has served as the Chairman of the Board since November 2018. Ms. Potter has served as the Chief Executive Officer of Sumitovant Biopharma, Inc., a biopharmaceutical company and a subsidiary of Sumitovant Biopharma Ltd. since December 2019. Sumitovant Biopharma Ltd. is our majority shareholder and a wholly-owned subsidiary of Sumitomo Dainippon Pharma. From July 2018 to December 2019 Ms. Potter served as Vant Operating Chair of Roivant Sciences, Inc, a pharmaceutical company. Ms. Potter founded Myrtle Potter & Company, LLC, a private healthcare and life sciences advisory firm, in September 2005 and served as its Chief Executive Officer until June 2018. From August 2009 until December 2014 Ms. Potter served as Founder and Chief Executive Officer of Myrtle Potter Media, Inc., a consumer healthcare company. From 2000 to 2004 Ms. Potter served as Chief Operating Officer at Genentech, Inc., a biopharmaceutical company, and from 2004 to 2005 she served as its President, Commercial Operations and Executive Vice President. Prior to that, Ms. Potter held various positions, including President, U.S. Cardiovascular/Metabolics at Bristol-Myers Squibb and as a Vice President at Merck & Co. Ms. Potter currently serves on the board of directors of Liberty Mutual Holding Company Inc., a diversified global insurance company and several privately held companies, including Urovant Sciences Ltd., a biopharmaceutical company which ceased to be a public company in March 2021 as a result of Sumitovant acquiring all of the outstanding shares of Urovant not previously held by Sumitovant. Ms. Potter previously served on the boards of directors of Axsome Therapeutics, Inc., a biopharmaceutical company, from June 2017 to June 2020 Immunovant, Inc., a biopharmaceutical company, from December 2019 to February 2020 Axovant Gene Therapies Ltd., a biopharmaceutical company, from September 2018 to February 2020 Arbutus Biopharma Corporation, a biopharmaceutical company, from October 2018 to February 2020 INSMED Incorporated, a biopharmaceutical company, from December 2014 to November 2018 Rite Aid Corporation, a leading drugstore chain, from December 2013 to September 2018 Everyday Health, Inc., a leading provider of digital health and wellness solutions, from October 2010 until its acquisition in December 2016 and Amazon.com, Inc., a leading e-commerce company, from 2004 to 2009. She also served on the boards of directors of Medco Health Solutions Inc. and Express Scripts Holding Co., subsequent to its acquisition of Medco Health Solutions, as well as other privately held companies. Ms. Potter earned a B.A. from the University of Chicago.
高管简历
中英对照 | 中文 | 英文- Matthew Lang
Matthew Lang自2017年7月起担任公司总法律顾问，自2018年9月起担任公司秘书。Lang先生目前还担任Myovant Sciences，Inc.的首席法律和行政官以及公司秘书。郎先生曾担任生物制药公司吉利德科学公司全球诉讼，调查，就业法和信息治理主管Vice President，2009年11月至2017年7月在该公司工作。在Gilead，除了领导法律部门内部的核心职能外，Lang先生还是公司企业运营集团，全球法律领导团队和全球合规委员会的成员。任职Gilead公司之前，他曾担任Dechert LLP（位于纽约市）的律师（从2003年到2009年），在那里他曾代表公司和高管处理监管执行事务、内部调查、刑事辩护事务、劳资纠纷和其他民事诉讼和上诉。朗先生于2015年至2018年担任联合途湾区董事会成员。Lang先生在加拿大金斯敦皇后大学（Queen&8217；s University at Kingston）获得古典研究学士学位，并在宾夕法尼亚大学法学院（University of Pennsylvania Law School）获得法学博士学位。
Matthew Lang has served as our General Counsel since July 2017 and as our Corporate Secretary since September 2018. Mr. Lang also currently serves as the Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. and is the General Manager of Myovant Sciences GmbH based in Basel, Switzerland. Mr. Lang was previously Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc., a biopharmaceutical company, where he worked from November 2009 to July 2017. At Gilead, in addition to leading core functions within the legal department, Mr. Lang was a member of the company’s Corporate Operating Group, Global Legal Leadership Team and the Global Compliance Committee. Prior to Gilead, from 2003 to 2009 Mr. Lang was an attorney at Dechert LLP in New York City, where he represented companies and executives in regulatory enforcement matters, internal investigations, criminal defense matters, labor disputes, and other civil litigation and appeals. Mr. Lang served as a member of the board of directors of the United Way Bay Area from 2015 to 2018. Mr. Lang received his B.A. in Classical Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.- Matthew Lang自2017年7月起担任公司总法律顾问，自2018年9月起担任公司秘书。Lang先生目前还担任Myovant Sciences，Inc.的首席法律和行政官以及公司秘书。郎先生曾担任生物制药公司吉利德科学公司全球诉讼，调查，就业法和信息治理主管Vice President，2009年11月至2017年7月在该公司工作。在Gilead，除了领导法律部门内部的核心职能外，Lang先生还是公司企业运营集团，全球法律领导团队和全球合规委员会的成员。任职Gilead公司之前，他曾担任Dechert LLP（位于纽约市）的律师（从2003年到2009年），在那里他曾代表公司和高管处理监管执行事务、内部调查、刑事辩护事务、劳资纠纷和其他民事诉讼和上诉。朗先生于2015年至2018年担任联合途湾区董事会成员。Lang先生在加拿大金斯敦皇后大学（Queen&8217；s University at Kingston）获得古典研究学士学位，并在宾夕法尼亚大学法学院（University of Pennsylvania Law School）获得法学博士学位。
- Matthew Lang has served as our General Counsel since July 2017 and as our Corporate Secretary since September 2018. Mr. Lang also currently serves as the Chief Legal and Administrative Officer and Corporate Secretary of Myovant Sciences, Inc. and is the General Manager of Myovant Sciences GmbH based in Basel, Switzerland. Mr. Lang was previously Vice President, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences, Inc., a biopharmaceutical company, where he worked from November 2009 to July 2017. At Gilead, in addition to leading core functions within the legal department, Mr. Lang was a member of the company’s Corporate Operating Group, Global Legal Leadership Team and the Global Compliance Committee. Prior to Gilead, from 2003 to 2009 Mr. Lang was an attorney at Dechert LLP in New York City, where he represented companies and executives in regulatory enforcement matters, internal investigations, criminal defense matters, labor disputes, and other civil litigation and appeals. Mr. Lang served as a member of the board of directors of the United Way Bay Area from 2015 to 2018. Mr. Lang received his B.A. in Classical Studies from Queen’s University at Kingston, Canada and his J.D. from the University of Pennsylvania Law School.
- Juan Camilo Arjona Ferreira
Juan Camilo Arjona Ferreira自2017年7月起担任Myovant Sciences，Inc.首席医疗官。2014年3月至2017年7月，Arjona Ferreira博士高级副总裁，制药公司Shionogi Inc.的临床开发，在那里他曾担任其美国高级领导团队和全球科学委员会成员，并负责领导其美国临床开发组织。2002年7月至2014年3月，Arjona Ferreira博士在制药公司默克制药公司工作，在那里他担任了越来越重要的职务，最后的职务是妇女健康临床研究执行主任，并领导了避孕和妇女健康所有项目的产品开发团队。他获得医学博士学位，并在哥伦比亚波哥大的Colegio Mayor del Rosario完成妇产科研究生专科培训。
Juan Camilo Arjona Ferreira has served as Chief Medical Officer of Myovant Sciences Ltd. and Myovant Sciences, Inc. since July 2017. From March 2014 to July 2017 Dr. Arjona Ferreira was Senior Vice President, Clinical Development at Shionogi Inc., a pharmaceutical company, where he served on its U.S. Senior Leadership Team and the Global Scientific Committee and was responsible for leading its U.S. Clinical Development organization. From July 2002 to March 2014 Dr. Arjona Ferreira worked at Merck & Co.,Inc., a pharmaceutical company, where he held positions of increased responsibility, the last being Executive Director of Clinical Research in Women’s Health and led the product development teams for all programs in contraception and women’s health. He received his M.D. and completed his postgraduate specialist training in Obstetrics and Gynecology at Colegio Mayor del Rosario in Bogota, Colombia.- Juan Camilo Arjona Ferreira自2017年7月起担任Myovant Sciences，Inc.首席医疗官。2014年3月至2017年7月，Arjona Ferreira博士高级副总裁，制药公司Shionogi Inc.的临床开发，在那里他曾担任其美国高级领导团队和全球科学委员会成员，并负责领导其美国临床开发组织。2002年7月至2014年3月，Arjona Ferreira博士在制药公司默克制药公司工作，在那里他担任了越来越重要的职务，最后的职务是妇女健康临床研究执行主任，并领导了避孕和妇女健康所有项目的产品开发团队。他获得医学博士学位，并在哥伦比亚波哥大的Colegio Mayor del Rosario完成妇产科研究生专科培训。
- Juan Camilo Arjona Ferreira has served as Chief Medical Officer of Myovant Sciences Ltd. and Myovant Sciences, Inc. since July 2017. From March 2014 to July 2017 Dr. Arjona Ferreira was Senior Vice President, Clinical Development at Shionogi Inc., a pharmaceutical company, where he served on its U.S. Senior Leadership Team and the Global Scientific Committee and was responsible for leading its U.S. Clinical Development organization. From July 2002 to March 2014 Dr. Arjona Ferreira worked at Merck & Co.,Inc., a pharmaceutical company, where he held positions of increased responsibility, the last being Executive Director of Clinical Research in Women’s Health and led the product development teams for all programs in contraception and women’s health. He received his M.D. and completed his postgraduate specialist training in Obstetrics and Gynecology at Colegio Mayor del Rosario in Bogota, Colombia.
- David Marek
David Marek自2021年1月起担任董事会成员和我们的首席执行官，以及Myovant Sciences，Inc.（我们的全资子公司）的首席执行官。Marek先生从2019年9月到2020年12月担任AxsomeTherapeutics，Inc.（制药公司）的首席商务官，在那里他领导建立商业能力，为预期的产品发布做准备。在加入Axsome之前，Marek先生从2017年6月到2019年8月担任Amgen，Inc.（制药公司）的副总裁兼神经科学业务部总经理。在安进，马雷克领导了美国的商业化战略，并推出了Aimovig预防偏头痛。在领导神经科学业务单元之前，他曾担任Amgen’；S美国炎症和肾病学业务的营销副总裁（从2015年6月到2017年6月），负责管理收入预测，产品战略，以及Amgen美国炎症和肾病学业务的业务规划。在Amgen之前，Marek先生是Turnstone Strategies LLC的负责人和所有者，该公司是一家咨询公司，提供健康与健康、数字健康、企业战略、营销和各种其他事务的咨询服务。在此之前，Marek先生担任Webmd HealthCorp.（健康信息服务供应商）的执行副总裁、消费者服务和商业战略官。在担任WebMD的这一职位之前，Marek先生是Saatchi&Saatchi医疗保健Advertising的总经理，这是一家跨国通信和广告代理网络。他的职业生涯始于礼来公司（一家制药公司），随后是AstraZeneca（一家跨国制药和生物技术公司），在那里他担任各种市场营销与销售职务，责任越来越大。他在华盛顿州立大学（Washington State University）获得工商管理学士学位。
David Marek has served as a member of the Board and our Principal Executive Officer, and as Chief Executive Officer of Myovant Sciences, Inc., our wholly-owned subsidiary, since January 2021. Mr. Marek served as Chief Commercial Officer of Axsome Therapeutics, Inc., a pharmaceutical company, where he led the buildout of commercial capabilities in preparation for anticipated product launches, from September 2019 to December 2020. Prior to joining Axsome, from June 2017 to August 2019 Mr. Marek held the position of Vice President, and General Manager of the Neuroscience business unit at Amgen, Inc., a pharmaceutical company. At Amgen, Mr. Marek led the U.S. commercialization strategy and launch of Aimovig for migraine prevention. Prior to heading the Neuroscience business unit, he was Vice President of Marketing of Amgen’s U.S. Inflammation and Nephrology business from June 2015 to June 2017 in which role he was responsible for managing revenue forecasts, product strategies, and business planning for the U.S. Inflammation and Nephrology business of Amgen. Before Amgen, Mr. Marek was the principal and owner of Turnstone Strategies LLC, which was a consulting firm providing consulting services on health and wellness, digital health, corporate strategy, marketing, and various other matters. Prior to that position, Mr. Marek served as Executive Vice President, Consumer Services, and Commercial Strategy Officer of WebMD Health Corp., a provider of health information services. Prior to this position at WebMD, Mr. Marek was the Managing Director of Saatchi & Saatchi Healthcare Advertising, a multinational communications and advertising agency network. Mr. Marek began his career at Eli Lilly and Company, a pharmaceutical company, followed by AstraZeneca, a multinational pharmaceutical and biotechnology company, where he served in a variety of marketing and sales roles of increasing responsibility. He earned his Bachelor of Arts degree in Business Administration from Washington State University.- David Marek自2021年1月起担任董事会成员和我们的首席执行官，以及Myovant Sciences，Inc.（我们的全资子公司）的首席执行官。Marek先生从2019年9月到2020年12月担任AxsomeTherapeutics，Inc.（制药公司）的首席商务官，在那里他领导建立商业能力，为预期的产品发布做准备。在加入Axsome之前，Marek先生从2017年6月到2019年8月担任Amgen，Inc.（制药公司）的副总裁兼神经科学业务部总经理。在安进，马雷克领导了美国的商业化战略，并推出了Aimovig预防偏头痛。在领导神经科学业务单元之前，他曾担任Amgen’；S美国炎症和肾病学业务的营销副总裁（从2015年6月到2017年6月），负责管理收入预测，产品战略，以及Amgen美国炎症和肾病学业务的业务规划。在Amgen之前，Marek先生是Turnstone Strategies LLC的负责人和所有者，该公司是一家咨询公司，提供健康与健康、数字健康、企业战略、营销和各种其他事务的咨询服务。在此之前，Marek先生担任Webmd HealthCorp.（健康信息服务供应商）的执行副总裁、消费者服务和商业战略官。在担任WebMD的这一职位之前，Marek先生是Saatchi&Saatchi医疗保健Advertising的总经理，这是一家跨国通信和广告代理网络。他的职业生涯始于礼来公司（一家制药公司），随后是AstraZeneca（一家跨国制药和生物技术公司），在那里他担任各种市场营销与销售职务，责任越来越大。他在华盛顿州立大学（Washington State University）获得工商管理学士学位。
- David Marek has served as a member of the Board and our Principal Executive Officer, and as Chief Executive Officer of Myovant Sciences, Inc., our wholly-owned subsidiary, since January 2021. Mr. Marek served as Chief Commercial Officer of Axsome Therapeutics, Inc., a pharmaceutical company, where he led the buildout of commercial capabilities in preparation for anticipated product launches, from September 2019 to December 2020. Prior to joining Axsome, from June 2017 to August 2019 Mr. Marek held the position of Vice President, and General Manager of the Neuroscience business unit at Amgen, Inc., a pharmaceutical company. At Amgen, Mr. Marek led the U.S. commercialization strategy and launch of Aimovig for migraine prevention. Prior to heading the Neuroscience business unit, he was Vice President of Marketing of Amgen’s U.S. Inflammation and Nephrology business from June 2015 to June 2017 in which role he was responsible for managing revenue forecasts, product strategies, and business planning for the U.S. Inflammation and Nephrology business of Amgen. Before Amgen, Mr. Marek was the principal and owner of Turnstone Strategies LLC, which was a consulting firm providing consulting services on health and wellness, digital health, corporate strategy, marketing, and various other matters. Prior to that position, Mr. Marek served as Executive Vice President, Consumer Services, and Commercial Strategy Officer of WebMD Health Corp., a provider of health information services. Prior to this position at WebMD, Mr. Marek was the Managing Director of Saatchi & Saatchi Healthcare Advertising, a multinational communications and advertising agency network. Mr. Marek began his career at Eli Lilly and Company, a pharmaceutical company, followed by AstraZeneca, a multinational pharmaceutical and biotechnology company, where he served in a variety of marketing and sales roles of increasing responsibility. He earned his Bachelor of Arts degree in Business Administration from Washington State University.
- Lauren Merendino
Lauren Merendino自2021年4月起担任Myovant SciencesLtd.和Myovant Sciences，Inc.的首席商务官。从2018年9月到2021年4月，Merendino女士担任Genentech，Inc.（制药公司）神经罕见疾病副总裁，在那里，她负责领导一个跨职能团队，以推出神经系统罕见疾病治疗领域的产品，并领导销售、营销、市场准入、医疗事务和政府事务及宣传方面的合作努力。从2009年9月到2018年9月，梅伦迪诺女士还在Genentech担任多个其他职位，在那里她在销售、营销、定价、市场准入和客户洞察力的商业组织中承担越来越多的责任，专注于神经科学和肿瘤领域。在加入Genentech之前，从1997年8月到2009年8月，梅伦迪诺女士在罗氏制药公司（Roche）担任过多个职位，她在该公司负责乳腺癌和结直肠癌领域的药品营销，主要负责战术规划和促销产品的执行、患者支持计划，医疗团队互动，销售团队界面，销售培训，顾问委员会和市场调研。在Roche and Genentech任职期间，她在国家销售、市场营销以及早期开发和商业开发交易中的分子商业策略方面拥有广泛的经验。她在宾夕法尼亚州立大学获得了微生物学学士学位，在纽约大学获得了营销和管理硕士学位。
Lauren Merendino has served as Chief Commercial Officer of Myovant Sciences Ltd. and Myovant Sciences, Inc. since April 2021. From September 2018 to April 2021 Ms. Merendino served as the Vice President of Neurological Rare Diseases at Genentech, Inc., a pharmaceutical company, where she was responsible for leading a cross-functional team to launch products in the neurological rare disease therapeutic area and for leading the collaboration efforts across sales, marketing, market access, medical affairs and government affairs and advocacy. Ms. Merendino also held various other positions at Genentech from September 2009 to September 2018 where she had increasing responsibility in the commercial organization across sales, marketing, pricing, market access, and customer insights, with a focus on the neuroscience and oncology areas. Before joining Genentech, from August 1997 to August 2009 Ms. Merendino held various positions at Roche, a pharmaceutical company, where she had increasing responsibilities for marketing drugs in the breast and colorectal cancer areas, with a focus on tactical planning and execution of promotional pieces, patient support programs, medical team interaction, sales team interface, sales training, advisory boards, and market research. Over her tenure at Roche and Genentech, she had broad experience in national sales, marketing, as well as commercial strategies for molecules in early development and business development deals. She earned her B.S. degree in Microbiology from Pennsylvania State University and her M.B.A. in Marketing and Management from New York University.- Lauren Merendino自2021年4月起担任Myovant SciencesLtd.和Myovant Sciences，Inc.的首席商务官。从2018年9月到2021年4月，Merendino女士担任Genentech，Inc.（制药公司）神经罕见疾病副总裁，在那里，她负责领导一个跨职能团队，以推出神经系统罕见疾病治疗领域的产品，并领导销售、营销、市场准入、医疗事务和政府事务及宣传方面的合作努力。从2009年9月到2018年9月，梅伦迪诺女士还在Genentech担任多个其他职位，在那里她在销售、营销、定价、市场准入和客户洞察力的商业组织中承担越来越多的责任，专注于神经科学和肿瘤领域。在加入Genentech之前，从1997年8月到2009年8月，梅伦迪诺女士在罗氏制药公司（Roche）担任过多个职位，她在该公司负责乳腺癌和结直肠癌领域的药品营销，主要负责战术规划和促销产品的执行、患者支持计划，医疗团队互动，销售团队界面，销售培训，顾问委员会和市场调研。在Roche and Genentech任职期间，她在国家销售、市场营销以及早期开发和商业开发交易中的分子商业策略方面拥有广泛的经验。她在宾夕法尼亚州立大学获得了微生物学学士学位，在纽约大学获得了营销和管理硕士学位。
- Lauren Merendino has served as Chief Commercial Officer of Myovant Sciences Ltd. and Myovant Sciences, Inc. since April 2021. From September 2018 to April 2021 Ms. Merendino served as the Vice President of Neurological Rare Diseases at Genentech, Inc., a pharmaceutical company, where she was responsible for leading a cross-functional team to launch products in the neurological rare disease therapeutic area and for leading the collaboration efforts across sales, marketing, market access, medical affairs and government affairs and advocacy. Ms. Merendino also held various other positions at Genentech from September 2009 to September 2018 where she had increasing responsibility in the commercial organization across sales, marketing, pricing, market access, and customer insights, with a focus on the neuroscience and oncology areas. Before joining Genentech, from August 1997 to August 2009 Ms. Merendino held various positions at Roche, a pharmaceutical company, where she had increasing responsibilities for marketing drugs in the breast and colorectal cancer areas, with a focus on tactical planning and execution of promotional pieces, patient support programs, medical team interaction, sales team interface, sales training, advisory boards, and market research. Over her tenure at Roche and Genentech, she had broad experience in national sales, marketing, as well as commercial strategies for molecules in early development and business development deals. She earned her B.S. degree in Microbiology from Pennsylvania State University and her M.B.A. in Marketing and Management from New York University.
- Frank Karbe
Frank Karbe， 他是董事。2010年1月以来，他一直担任我们的董事。他目前担任Exelixis公司（在纳斯达克上市的生物技术公司）的执行副总裁和首席财务官。他于2004年加入Exelixis公司。他曾担任高盛投资公司（Goldman Sachs）的投资银行家，在那里他最近担任医疗保健集团的副总裁，专注于生物技术产业的企业融资和并购。1997年加入高盛投资公司（Goldman Sachs）之前，他曾担任The Royal Dutch/Shell Group公司（位于欧洲）的财务部门的多种职务。他持有 the WHU-Otto Beisheim Graduate School of Management（位于德国科布伦茨）的理科硕士学位，相当于美国工商管理硕士学位。
Frank Karbe has served as our Principal Financial and Accounting Officer since September 2016. Mr. Karbe was appointed as Myovant Sciences, Inc.'s Chief Financial Officer in April 2017 and was subsequently appointed as President and Chief Financial Officer in February 2020. From September 2014 to July 2016 Mr. Karbe served as President of The Color Run, a global mass participation events platform, where he was responsible for leading the operational and financial functions. From January 2004 to June 2014 Mr. Karbe was the Executive Vice President and Chief Financial Officer of Exelixis, Inc., a biotechnology company. During his tenure at Exelixis, Mr. Karbe was responsible for leading the finance organization, internal and external communications, business development, information technology, corporate strategy and various other operational functions. Prior to joining Exelixis in 2004 Mr. Karbe worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group advising clients on corporate finance and mergers and acquisitions. Prior to joining Goldman Sachs in 1997 Mr. Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. Mr. Karbe served as a director of Aduro Biotech, Inc. from April 2019 to October 2020 when Aduro Biotech was merged with Chinook Therapeutics, Inc. Mr. Karbe also served as a director of Arbutus Biopharma Corporation from 2010 to 2018. Mr. Karbe received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate School of Management, Koblenz, Germany.- Frank Karbe， 他是董事。2010年1月以来，他一直担任我们的董事。他目前担任Exelixis公司（在纳斯达克上市的生物技术公司）的执行副总裁和首席财务官。他于2004年加入Exelixis公司。他曾担任高盛投资公司（Goldman Sachs）的投资银行家，在那里他最近担任医疗保健集团的副总裁，专注于生物技术产业的企业融资和并购。1997年加入高盛投资公司（Goldman Sachs）之前，他曾担任The Royal Dutch/Shell Group公司（位于欧洲）的财务部门的多种职务。他持有 the WHU-Otto Beisheim Graduate School of Management（位于德国科布伦茨）的理科硕士学位，相当于美国工商管理硕士学位。
- Frank Karbe has served as our Principal Financial and Accounting Officer since September 2016. Mr. Karbe was appointed as Myovant Sciences, Inc.'s Chief Financial Officer in April 2017 and was subsequently appointed as President and Chief Financial Officer in February 2020. From September 2014 to July 2016 Mr. Karbe served as President of The Color Run, a global mass participation events platform, where he was responsible for leading the operational and financial functions. From January 2004 to June 2014 Mr. Karbe was the Executive Vice President and Chief Financial Officer of Exelixis, Inc., a biotechnology company. During his tenure at Exelixis, Mr. Karbe was responsible for leading the finance organization, internal and external communications, business development, information technology, corporate strategy and various other operational functions. Prior to joining Exelixis in 2004 Mr. Karbe worked as an investment banker for Goldman Sachs & Co., where he served most recently as Vice President in the healthcare group advising clients on corporate finance and mergers and acquisitions. Prior to joining Goldman Sachs in 1997 Mr. Karbe held various positions in the finance department of The Royal Dutch/Shell Group in Europe. Mr. Karbe served as a director of Aduro Biotech, Inc. from April 2019 to October 2020 when Aduro Biotech was merged with Chinook Therapeutics, Inc. Mr. Karbe also served as a director of Arbutus Biopharma Corporation from 2010 to 2018. Mr. Karbe received his Diplom-Kaufmann from the WHU-Otto Beisheim Graduate School of Management, Koblenz, Germany.